Comparison 1. Tamafidis versus placebo in TTR‐FAP.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Severity of peripheral neuropathy (expressed as the change from baseline in NIS‐LL)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 12 months	1	125	Mean Difference (IV, Fixed, 95% CI)	‐3.83 [‐5.99, ‐1.67]
1.2 18 months	1	125	Mean Difference (IV, Fixed, 95% CI)	‐3.21 [‐5.63, ‐0.79]
2 Change in mBMI	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 12 months	1	125	Mean Difference (IV, Fixed, 95% CI)	50.2 [24.46, 75.94]
2.2 18 months	1	125	Mean Difference (IV, Fixed, 95% CI)	70.6 [41.96, 99.24]
3 Quality of life (expressed as the change from baseline in Norfolk QOL‐DN total score)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 12 months	1	125	Mean Difference (IV, Fixed, 95% CI)	‐3.50 [‐9.48, 2.48]
3.2 18 months	1	125	Mean Difference (IV, Fixed, 95% CI)	‐4.5 [‐11.27, 2.27]
4 Number of participants who died during the trial (published paper ‐ see text)	1	128	Risk Ratio (M‐H, Fixed, 95% CI)	0.65 [0.11, 3.74]
5 Number of participants experiencing at least one adverse event	1	128	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.88, 1.04]
6 Number of participants experiencing mild adverse events	1	128	Risk Ratio (M‐H, Fixed, 95% CI)	0.99 [0.87, 1.12]
7 Number of dropouts due to adverse events	1	128	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.30, 5.54]
8 Number of participants experiencing at least one severe adverse event	1	128	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.37, 3.62]